Piper Jaffray Companies restated their buy rating on shares of Glaukos Corporation (NYSE:GKOS) in a research report report published on Thursday morning. The firm currently has a $56.00 target price on the medical instruments supplier’s stock.
A number of other analysts have also recently weighed in on GKOS. Roth Capital lowered their price target on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating on the stock in a report on Thursday. Zacks Investment Research upgraded shares of Glaukos Corporation from a hold rating to a buy rating and set a $46.00 price target on the stock in a report on Friday, July 21st. BidaskClub cut shares of Glaukos Corporation from a buy rating to a hold rating in a report on Wednesday, July 12th. BMO Capital Markets restated a buy rating and issued a $54.00 price target on shares of Glaukos Corporation in a report on Tuesday, April 11th. Finally, Stephens upgraded shares of Glaukos Corporation from an equal weight rating to an overweight rating in a report on Monday, May 8th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. Glaukos Corporation has an average rating of Buy and an average target price of $52.33.
Shares of Glaukos Corporation (NYSE GKOS) traded down 1.36% on Thursday, hitting $36.26. 1,014,990 shares of the stock traded hands. Glaukos Corporation has a 52-week low of $28.26 and a 52-week high of $52.49. The stock has a market cap of $1.25 billion, a P/E ratio of 329.64 and a beta of 1.29. The stock’s 50 day moving average price is $41.36 and its 200 day moving average price is $43.37.
WARNING: This article was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/06/glaukos-corporations-nysegkos-buy-rating-reiterated-at-piper-jaffray-companies.html.
Hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in Glaukos Corporation by 6.9% in the fourth quarter. State Street Corp now owns 281,407 shares of the medical instruments supplier’s stock worth $9,653,000 after buying an additional 18,183 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Glaukos Corporation during the fourth quarter valued at approximately $513,000. Engineers Gate Manager LP acquired a new stake in shares of Glaukos Corporation during the first quarter valued at approximately $372,000. William Blair Investment Management LLC boosted its stake in shares of Glaukos Corporation by 5.3% in the first quarter. William Blair Investment Management LLC now owns 2,064,444 shares of the medical instruments supplier’s stock valued at $105,906,000 after buying an additional 104,670 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 1,506 shares during the last quarter. Institutional investors own 89.63% of the company’s stock.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
